Brenntag's Q2: The Art of the Inventory Gain

New CEO Jens Birgersson reframes a working-capital blip as commercial momentum, but H2 guidance keeps the powder dry.

BNR.DE · Earnings Call · 2026-08-12

A temporary technical effect with a silver lining

Brenntag's second-quarter 2026 call, held on August 12, was dominated by a single phrase from CFO Thomas Reisten: “temporary technical effect” — Thomas Reisten, Chief Financial Officer (CFO) · 2026-08-12. The company reported EUR 353 million of working-capital outflow, which in an 11% sales-growth quarter might seem normal—except that the cause was not volume but pricing. Reisten explained that the inventory build came from "the pricing side of our inventory,” not increased stock. Early in the quarter, Brenntag sold lower-cost inventory at higher market prices, then replenished at elevated costs. This is a classic inventory gain, though Reisten was quick to note it was not a revaluation but a realized margin on older stock. He added, "We haven't seen significant product shortages and have been able to continue to safely deliver to our customers," a sign that the Middle East supply disruption has not broken the supply chain. For CEO Jens Birgersson, this was replenishment costs doing what they do in a rising-price environment—they created an over-earning opportunity. Yet the narrative was deliberately framed as more than a windfall. Birgersson stressed that the company is "playing on a higher price level on the sourcing side" and that the volatility itself is a tailwind. This is the heart of the quarter: a distributor that benefits from scarcity, but whose management wants investors to see the underlying commercial engine, not just the cyclical bump.

We are less strict with – we don't look so much at competition. We look at ourselves and we play to our strength, which means that we are a little bit less focused on gross profit per tonne, focus on gross profit, we focus on customers.
Jens Birgersson, Chief Executive Officer (CEO) · 2026-08-12

Bonus provisions and the cost program

The other big swing was personnel costs, which rose sharply year-on-year. Reisten attributed the bulk to higher bonus provisions, a direct result of outperforming initial guidance. "We've been quite transparent that there's bonus provisions and other effects in the second quarter of about EUR 40 million," he said. This is the bonus provision story that has appeared in Brenntag's keyword trajectory before, but this quarter it has a positive spin: the company is paying for performance. The cost-savings program, meanwhile, is on track to deliver EUR 150 million this year, with a run rate of EUR 41 million already achieved. Birgersson framed this as a "proof point" for the broader productivity journey, not a hard stop. "This is just the beginning of a productivity raise and competitiveness raise," he said, pointing to structural savings that will persist beyond 2026.

Commercial self-help, not just market

Birgersson used the call to make the case that volume growth is increasingly self-generated. He called out the success in reactivating dormant accounts: "We have 1,000 customers that didn't buy from us that have been dormant that we have gotten back." That is a concrete, company-unique data point. He also described a shift in sales incentives, moving away from gross-profit-per-tonne targets toward customer-centric selling. The sales incentives were explicitly cited as a lever being sharpened. This is a notable philosophical change from the previous CEO, who had emphasized margin management over volume. Birgersson is now arguing that growth in a flat chemical market must come from share gains and cross-selling, especially using the Essential sales force to open doors for Specialties. The Specialty business, or BSP, showed strong sequential volume improvement, with gross-profit margin up 0.6 percentage points and EBITDA conversion up 3.3 points, according to Reisten. "We see that a lot of that improvement is because people are selling more," Birgersson said.

Guidance and the H2 conservatism

Despite the strong first half, management kept full-year guidance unchanged, implying a sharp deceleration in H2. Reisten was explicit that the midpoint assumes Q3 gross profit will "moderate step-by-step down" and Q4 will be "relatively similar to the previous year." Analysts pressed on the implied Q3 EBITDA of EUR 400–420 million, and Reisten did not confirm but did not push back hard. The conservatism is partly about the normalization of the inventory gains and partly about demand destruction risk. Birgersson noted that if the Hormuz crisis resolves and oil price levels drop, margins will contract. "Higher overall price levels are better for us and a little bit of the volatility better for us," he said, but the assumption is that the conflict and its price effects will persist. This is a marked contrast to prior quarters. In the 2024 call, Christian Kohlpaintner had said the Specialties business's performance gap was "inferior to the supplier and product portfolio" of pure-play peers. Now Birgersson is arguing the portfolio is less of a constraint, and the company is taking share through execution. The shift in tone is the real news. For investors, the question is whether Q2's earnings quality is sustainable. The working-capital swing will reverse, but the commercial initiatives—AI-driven pricing, customer analytics, and sales-force alignment—are structural. The prior call's destocking fears (from 2025) seem to have subsided, replaced by a more constructive, if cautious, outlook. Brenntag has found a new narrative: it is not just a leveraged play on chemical prices, but a business that can manufacture growth even when the tide is flat.